Mayzent

Active Ingredient(s): Siponimod
FDA Approved: * March 26, 2019
Pharm Company: * NOVARTIS PHARMS CORP
Category: Multiple Sclerosis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Mayzent Overview

Siponimod, marketed under the trade name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.[2] In March 2019, it was approved in the United States to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[1] Contents 1 M...

Read more Mayzent Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Siponimod

Recent Mayzent Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Mayzent: (2 results)

Sorted by National Drug Code

• 0078-0979 Mayzent .25 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation
• 0078-0986 Mayzent 2 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation

Other drugs which contain Siponimod or a similar ingredient: (1 result)

• SIPONIMOD